

# Richard A Watts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3758417/publications.pdf>

Version: 2024-02-01

120  
papers

9,557  
citations

61687

45  
h-index

45040

94  
g-index

126  
all docs

126  
docs citations

126  
times ranked

6020  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2022, 74, 1013-1018.	1.5	4
2	Global epidemiology of vasculitis. <i>Nature Reviews Rheumatology</i> , 2022, 18, 22-34.	3.5	112
3	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 386-392.	2.9	50
4	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 309-314.	0.5	157
5	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	2.9	71
6	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 321-326.	0.5	112
7	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	2.9	62
8	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 315-320.	0.5	145
9	Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?. <i>Current Rheumatology Reports</i> , 2022, 24, 111-117.	2.1	1
10	Response to: Correspondence on "2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis"™ by Joanna C Robson <i>et al</i> and "2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis"™ by Ravi Suppiah <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrheumdis-2022-222362.	0.5	12
11	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1089-1089.	2.9	0
12	Pulmonary involvement in primary systemic vasculitides. <i>Rheumatology</i> , 2021, 61, 319-330.	0.9	16
13	Patient perceptions of physical activity after a diagnosis of Giant Cell Arteritis: analysis of multinational qualitative data. <i>Arthritis Care and Research</i> , 2021, , .	1.5	1
14	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , 2021, 60, 617-628.	0.9	22
15	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.5	667
16	Cardiovascular risk factors associated with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Study. <i>Rheumatology</i> , 2020, 59, 319-323.	0.9	11
17	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	1.5	77
18	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 667-676.	2.9	33

#	ARTICLE	IF	CITATIONS
19	Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. <i>Rheumatology</i> , 2020, 59, 2316-2324.	0.9	34
20	Retinal vasculometric characteristics and their associations with polymyalgia rheumatica and giant cell arteritis in a prospective cohort: EPIC-Norfolk Eye Study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 547-549.	0.5	0
21	P182 Prevalence and mortality of ANCA-associated vasculitis in England. <i>Rheumatology</i> , 2020, 59, .	0.9	2
22	P185 Patient perceptions of physical activity following a diagnosis of giant cell arteritis: a multinational qualitative study. <i>Rheumatology</i> , 2020, 59, .	0.9	1
23	The value of case reports in democratising evidence from resource-limited settings: results of an exploratory survey. <i>Health Research Policy and Systems</i> , 2020, 18, 84.	1.1	1
24	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1741-1747.	2.9	31
25	O36 Validation of methods to enable national registration for rare autoimmune rheumatic diseases. <i>Rheumatology</i> , 2020, 59, .	0.9	5
26	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	0.9	5
27	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32.	0.9	42
28	Clinical associations of renal involvement in ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102495.	2.5	47
29	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
30	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
31	Early development of new cardiovascular risk factors in the systemic vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 126-134.	0.4	2
32	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	5.8	160
33	185 GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. <i>Rheumatology</i> , 2019, 58, .	0.9	0
34	Should proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibody vasculitis be treated differently: part 1. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 381-383.	0.4	1
35	Impact of caring for someone with a rare rheumatic condition, views from patients and informal carers the need for cat-like vigilance. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz003.	0.3	7
36	Giant cell arteritis: new concepts, treatments and the unmet need that remains. <i>Rheumatology</i> , 2019, 58, 1123-1125.	0.9	17

#	ARTICLE	IF	CITATIONS
37	Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 704-705.	0.5	2
38	Evolving concepts in classification of systemic vasculitis: where are we and what is the way forward?. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 21-27.	0.9	13
39	Can prediction models in primary care enable earlier diagnosis of rare rheumatic diseases?. <i>Rheumatology</i> , 2018, 57, 2065-2066.	0.9	7
40	Novel insights into the aetiology of granulomatosis with polyangiitis—a case-control study using the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2018, 57, 1002-1010.	0.9	13
41	151 Is ANCA-associated vasculitis more common in areas with more polluted air?. <i>Rheumatology</i> , 2018, 57, .	0.9	0
42	Introduction, epidemiology and classification of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 3-20.	1.4	69
43	Outcomes and compliance with standards of care in anti-neutrophil cytoplasmic antibody-associated vasculitis—insights from a large multiregion audit. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky025.	0.3	5
44	Cardiovascular risk factors are associated with the onset of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in a prospective cohort: EPIC-Norfolk study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
45	Mortality in granulomatosis with polyangiitis: a population-based case control study. <i>Rheumatology</i> , 2018, 57, .	0.9	1
46	The global burden of anti-neutrophil cytoplasmic antibody vasculitis. <i>Rheumatology</i> , 2017, 56, kew438.	0.9	1
47	The association of vascular risk factors with visual loss in giant cell arteritis. <i>Rheumatology</i> , 2017, 56, kew397.	0.9	16
48	Educating people with rare rheumatological conditions. <i>Rheumatology</i> , 2017, 56, kew487.	0.9	0
49	ANCA-associated vasculitis. <i>Clinical Medicine</i> , 2017, 17, 60-64.	0.8	153
50	Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?. <i>Rheumatology</i> , 2017, 56, 1154-1161.	0.9	89
51	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
52	Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2017, 56, 1962-1969.	0.9	48
53	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017, 3, e000449.	1.8	23
54	Welcome to <i>Rheumatology Advances in Practice</i> . <i>Rheumatology Advances in Practice</i> , 2017, 1, rlx001.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1-2.	0.4	11
56	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1583-1594.	0.5	940
57	The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink. <i>Rheumatology</i> , 2016, 56, kew413.	0.9	22
58	Vasculitis and inflammatory arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 916-931.	1.4	16
59	Refractory rheumatoid vasculitis—a therapeutic dilemma. <i>Oxford Medical Case Reports</i> , 2016, 2016, omw081.	0.2	1
60	Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. <i>Rheumatology</i> , 2016, 55, 1656-1663.	0.9	54
61	Epidemiology of vasculitis —“ Lessons learnt from the differences in different geographical areas. <i>Indian Journal of Rheumatology</i> , 2015, 10, S6-S10.	0.2	2
62	Biomarkers of early stage osteoarthritis, rheumatoid arthritis and musculoskeletal health. <i>Scientific Reports</i> , 2015, 5, 9259.	1.6	47
63	Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. <i>Arthritis Research and Therapy</i> , 2015, 17, 195.	1.6	40
64	Association between environmental exposures and granulomatosis with polyangiitis in Canterbury, New Zealand. <i>Arthritis Research and Therapy</i> , 2015, 17, 333.	1.6	14
65	009.€Eosinophilic Fasciitis Secondary to Ranibizumab Injections. <i>Rheumatology</i> , 2015, , .	0.9	1
66	The outcome and cost-effectiveness of nurse-led care in the community for people with rheumatoid arthritis: a non-randomised pragmatic study. <i>BMJ Open</i> , 2015, 5, e007696.	0.8	21
67	Granulomatosis with polyangiitis granulomata show increased uptake of FDG. <i>Rheumatology</i> , 2015, 54, 544-544.	0.9	0
68	Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, i14-i22.	0.4	183
69	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
70	HLA allele variation as a potential explanation for the geographical distribution of granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 359-362.	0.9	24
71	Takayasu Arteritis. , 2015, , 53-62.		0
72	How to investigate multisystem disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 831-843.	1.4	6

#	ARTICLE	IF	CITATIONS
73	How to investigate rheumatological diseases?. Best Practice and Research in Clinical Rheumatology, 2014, 28, 829-830.	1.4	0
74	The informational needs of patients with ANCA-associated vasculitis--development of an informational needs questionnaire. Rheumatology, 2014, 53, 1414-1421.	0.9	20
75	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology, 2014, 53, 2306-2309.	0.9	246
76	Editorial. Oxford Medical Case Reports, 2014, 2014, 39-39.	0.2	0
77	P10. Review of the expert panel methodology in the diagnostic and classification criteria for vasculitis study: a pilot study. Rheumatology, 2014, 53, i15-i16.	0.9	1
78	Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology, 2014, 53, 145-152.	0.9	75
79	Classification of vasculitis: From historical controversies to present day pragmatic consensus. Indian Journal of Rheumatology, 2014, 9, 120-126.	0.2	1
80	Rheumatoid vasculitisâ€”down but not out. Nature Reviews Rheumatology, 2014, 10, 261-262.	3.5	3
81	â€œIn One Ear and Out the Other â€œ It's a Lot to Take inâ€™: A Qualitative Study Exploring the Informational Needs of Patients with ANCAâ€™Associated Vasculitis. Musculoskeletal Care, 2013, 11, 51-59.	0.6	20
82	L32. ANCA vasculitis over the world. What do we learn from country differences?. Presse Medicale, 2013, 42, 591-593.	0.8	8
83	Epidemiology and clinical features of systemic vasculitis. Clinical and Experimental Nephrology, 2013, 17, 607-610.	0.7	61
84	ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clinical and Experimental Nephrology, 2013, 17, 619-621.	0.7	158
85	Classification of vasculitis: EMA classification using CHCC 2012 definitions. Annals of the Rheumatic Diseases, 2013, 72, 1888.2-1888.	0.5	35
86	Classification of ANCA-Associated Vasculitis. Current Rheumatology Reports, 2013, 15, 383.	2.1	40
87	ANCA vasculitis: to lump or split?. Rheumatology, 2012, 51, 2115-2117.	0.9	33
88	The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumatology, 2012, 51, 926-931.	0.9	116
89	The role of biologics in treatment of ANCA-associated vasculitis. Modern Rheumatology, 2012, 22, 319-326.	0.9	2
90	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology, 2012, 51, 634-643.	0.9	102

#	ARTICLE	IF	CITATIONS
91	An evaluation of rheumatology practitioner outreach clinics: a qualitative study. BMC Health Services Research, 2012, 12, 119.	0.9	5
92	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	13.9	820
93	The role of biologics in treatment of ANCA-associated vasculitis. Modern Rheumatology, 2012, 22, 319-326.	0.9	4
94	Systemic vasculitis--is it time to reclassify?. Rheumatology, 2011, 50, 643-645.	0.9	41
95	Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology, 2011, 50, 1916-1920.	0.9	283
96	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2011, 70, 704-704.	0.5	106
97	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. Arthritis and Rheumatism, 2011, 63, 863-864.	6.7	244
98	Granulomatosis with Polyangiitis (Wegener's). Journal of the American Society of Nephrology: JASN, 2011, 22, 587-588.	3.0	49
99	Polyarteritis nodosa and microscopic polyangiitis. , 2011, , 1523-1533.e1.		3
100	Pulmonary haemorrhage in ANCA-associated vasculitis. Rheumatology, 2010, 49, 1410-1412.	0.9	18
101	Epidemiology of ANCA-associated Vasculitis. Rheumatic Disease Clinics of North America, 2010, 36, 447-461.	0.8	180
102	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.5	139
103	The epidemiology of Takayasu arteritis in the UK. Rheumatology, 2009, 48, 1008-1011.	0.9	181
104	Recent developments in the classification and assessment of vasculitis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 429-443.	1.4	49
105	Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database. Arthritis and Rheumatism, 2009, 61, 1412-1416.	6.7	104
106	Hypotheses on the Etiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 237-252.	2.2	94
107	Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype?. Nephrology Dialysis Transplantation, 2008, 23, 3928-3931.	0.4	95
108	Seasonal variations in onset of Wegener's granulomatosis: increased in summer?. Journal of Rheumatology, 2007, 34, 889-90; author reply 890.	1.0	5

#	ARTICLE	IF	CITATIONS
109	Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 222-227.	0.5	1,041
110	What is known about the epidemiology of the vasculitides?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 191-207.	1.4	129
111	Epidemiology of the Vasculitides. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2004, 25, 455-464.	0.8	82
112	Does the introduction of a simple wedge to school seating reduce adolescent back pain?. <i>International Journal of Therapy and Rehabilitation</i> , 2004, 11, 462-466.	0.1	2
113	Are environmental factors important in primary systemic vasculitis?: A case-control study. <i>Arthritis and Rheumatism</i> , 2003, 48, 814-823.	6.7	186
114	Epidemiology of the vasculitides. <i>Current Opinion in Rheumatology</i> , 2003, 15, 11-16.	2.0	61
115	Epidemiology of Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, S1184-S1184.	0.6	15
116	Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. <i>Arthritis and Rheumatism</i> , 2000, 43, 414.	6.7	435
117	Wegener's granulomatosis: unusual presentations. <i>British Journal of Hospital Medicine</i> , 2000, 61, 250-253.	0.3	15
118	Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. <i>Arthritis and Rheumatism</i> , 1996, 39, 1208-1212.	6.7	107
119	317.â€¢Re-Appraisal of the 1990 American College of Rheumatology Classification Criteria for Systemic Vasculitis: Analysis of Data from the Diagnostic and Classification Criteria in Vasculitis Study. <i>Rheumatology</i> , 0, , .	0.9	0
120	277â€¢Using the Birmingham Vasculitis Activity Score as a Screening Tool in Patients with Suspected Vasculitis. <i>Rheumatology</i> , 0, , .	0.9	0